Will Richard Chen lead Personalis, Inc. as its new President? Yes, he has been appointed to this position effective March 13, 2026.
Chen’s appointment follows a successful tenure within the company, where he has served as Executive Vice President of Research and Development since March 2023 and as Chief Medical Officer since July 2021. His extensive experience in the biotechnology sector is expected to guide Personalis in its future endeavors.
As part of his new role, Chen’s annual base salary will be increased to $570,000, effective April 1, 2026. Additionally, his performance bonus target has been raised to 70% of his then-current annual base salary, reflecting the company’s confidence in his leadership capabilities.
Richard Chen co-founded Ingenuity Systems in August 1997, demonstrating his long-standing commitment to innovation in the field. He holds a B.S. in Computer Science, an M.S. in Medical Informatics, and an M.D., all from Stanford University, underscoring his strong academic background.
Before his current roles, Chen served as Senior Vice President of R&D from July 2021 to March 2023 and as Chief Scientific Officer from November 2011 to July 2021. His involvement in the clinical faculty at Stanford University School of Medicine since September 2011 further enhances his credentials.
Details remain unconfirmed regarding the specific strategic initiatives Chen plans to implement as President. However, his track record suggests a focus on advancing the company’s research and development capabilities.
As Personalis, Inc. moves forward under Chen’s leadership, stakeholders will be keenly watching how his vision translates into action and what new directions the company may take in the competitive biotechnology landscape.
